Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis

New England Journal of Medicine

Volumn 373, Issue 27, 2015, Pages 2618-2628

  Curry, M P ^a   O'Leary, J G ^a   Bzowej, N ^a   Muir, A J ^a   Korenblat, K M ^a   Fenkel, J M ^a   Reddy, K R ^a   Lawitz, E ^a   Flamm, S L ^a   Schiano, T ^a   Teperman, L ^a   Fontana, R ^a   Schiff, E ^a   Fried, M ^a   Doehle, B ^a   An, D ^a   McNally, J ^a   Osinusi, A ^a   Brainard, D M ^a   McHutchison, J G ^a   Brown, R S ^a   Charlton, M ^a   more..

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBAVIRIN; SOFOSBUVIR PLUS VELPATASVIR; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; DRUG COMBINATION; FUSED HETEROCYCLIC RINGS; NS-5 PROTEIN, HEPATITIS C VIRUS; SOFOSBUVIR; VELPATASVIR; VIRAL PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CHILD PUGH SCORE; CONTROLLED STUDY; COUGHING; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEMOLYSIS; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; HYPERBILIRUBINEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PHARMACOLOGICAL PARAMETERS; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARBAMATES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RIBAVIRIN; SOFOSBUVIR; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84952931354     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1512614     Document Type: Article

References (23)

1. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-21.
2. Afdhal N, Everson G, Calleja JL, et al. Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. Presented at the 49th Annual Meeting of the European Association for the Study of the Liver, London, April 913, 2014. abstract.
3. Forns X, Charlton M, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 2015; 61: 1485-94.
4. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649-59.
5. Manns M, Forns X, Samuel D, et al. Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post-liver transplantation patients with HCV infection: preliminary results of the SOLAR-2 trial. Presented at the 50th Annual Meeting of the European Association for the Study of the Liver, Vienna, April 2226, 2015. abstract.
6. Reddy KR, Lim JK, Kuo A, et al. All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: report from HCV-TARGET. Presented at the 50th Annual Meeting of the European Association for the Study of the Liver, Vienna, April 2226, 2015. abstract.
7. Poordad F. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 study. J Hepatol 2015; 62: Suppl: S261-S262.
8. Foster GR, McLaughlan J, Irving W, et al. Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effectivein HCV genotypes 1 and 3. Presented at the 48th Annual Meeting of the European Association for the Study of the Liver, Amsterdam, April 2428, 2013. abstract.
9. Deterding K, Her Zu Siederdissen C, Port K, et al. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Aliment Pharmacol Ther 2015; 42: 889-901.
10. Modi AA, Nazario H, Trotter JF, et al. Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis. Liver Transpl 2015 September 3 (Epub ahead of print).
11. Saxena V, Nyberg L, Pauly M, et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis. Hepatology 2015; 62: 715-25.
12. Harvoni (ledipasvir and sofosbuvir) tablets. European prescribing information. Cambridge, United Kingdom: Gilead Sciences International (http://www.ema .europa .eu/docs/en-GB/document-library/EPAR-Product-Information/human/003850/WC500177995 .pdf).
13. Sovaldi (sofosbuvir) tablets: U.S. prescribing information. Foster City, CA: Gilead Sciences, August 2015 (http://www.gilead .com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi-pi .pdf).
14. Harvoni (ledipasvir and sofosbuvir) tablets: U.S. prescribing information. Foster City, CA: Gilead Sciences, March 2015 (http://www .gilead .com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni-pi .pdf).
15. Cheng G, Yu M, Peng B, et al. GS-5816 A second generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage and a high resistance barrier. Presented at the 48th Annual Meeting of the European Association for the Study of the Liver, Amsterdam, April 2428, 2013. abstract.
16. Doehle B, Dvory-Sobol H, Hebner C, et al. Deep sequencing of HCV NS5A from a 3-day study of GS-5816 monotherapy confirms the potency of GS-5816 against pre-existing genotype 13 NS5A resistance-associated variants. Presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, November 15, 2013. abstract.
17. Lawitz E, Freilich B, Link J, et al. A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus. J Viral Hepat 2015; 22: 1011-9.
18. Everson GT, Towner WJ, Davis MN, et al. Sofosbuvir with velpatasvir in treatment- naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial. Ann Intern Med 2015 November 10 (Epub ahead of print).
19. Pianko S, Flamm SL, Shiffman ML, et al. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Ann Intern Med 2015 November 10 (Epub ahead of print).
20. Feld JJ, Jacobson IM, Hode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015;373:2599-607.
21. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015;373:2608-17.
22. Dyson JK, Hutchinson J, Harrison L, et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol 2015 August 29 (Epub ahead of print).
23. Fink SA, Jacobson IM. Managing patients with hepatitis-B-related or hepatitis- C-related decompensated cirrhosis. Nat Rev Gastroenterol Hepatol 2011; 8: 285-95.